Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APEN Apollo Endosurgery (APEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Apollo Endosurgery alerts: Email Address About Apollo Endosurgery Stock (NASDAQ:APEN) 30 days 90 days 365 days Advanced Chart Ad Genesis Gold GroupKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Apollo Endosurgery alerts:Sign Up Key Stats Today's Range N/A50-Day Range$9.87▼$10.0052-Week Range N/AVolume1.66 million shsAverage Volume1.43 million shsMarket Capitalization$579.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewApollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.Read More… Kamala’s tax plan is worse than you think—find out why (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive APEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter. Email Address APEN Stock News HeadlinesApollo Pipes Ltd 531761February 1, 2024 | morningstar.comAstronaut Frank Borman, commander of the first Apollo mission to the moon, dead at 95November 12, 2023 | nypost.com44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.September 25, 2024 | InvestorPlace (Ad)Apollo astronaut Ken Mattingly, who helped save the crew of Apollo 13, has diedNovember 5, 2023 | cnn.comGastric Band and Gastric Balloon Market to Witness Growth Acceleration | Apollo Endosurgery, Cousin Surgery, Spatz FGIA IncMay 10, 2023 | marketwatch.comApollo Endosurgery Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2023 | finance.yahoo.comAPEN Apollo Endosurgery, Inc.March 29, 2023 | seekingalpha.comDoes This Valuation Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Imply Investors Are Overpaying?March 7, 2023 | finance.yahoo.comSee More Headlines APEN Stock Analysis - Frequently Asked Questions How were Apollo Endosurgery's earnings last quarter? Apollo Endosurgery, Inc. (NASDAQ:APEN) posted its earnings results on Sunday, October, 31st. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. The biotechnology company had revenue of $16.35 million for the quarter, compared to the consensus estimate of $16.20 million. Apollo Endosurgery had a negative net margin of 51.84% and a negative trailing twelve-month return on equity of 89.48%. What other stocks do shareholders of Apollo Endosurgery own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE) and Sunesis Pharmaceuticals (SNSS). Company Calendar Last Earnings10/31/2021Today9/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:APEN CUSIPN/A CIK1251769 Webwww.apolloendo.com Phone(512) 279-5100Fax858-678-0900Employees202Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,840,000.00 Net Margins-51.84% Pretax Margin-51.08% Return on Equity-89.48% Return on Assets-33.76% Debt Debt-to-Equity Ratio1.04 Current Ratio2.35 Quick Ratio1.89 Sales & Book Value Annual Sales$76.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / BookN/AMiscellaneous Outstanding Shares57,972,000Free Float47,943,000Market Cap$579.72 million OptionableNot Optionable Beta2.31 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:APEN) was last updated on 9/25/2024 by MarketBeat.com Staff From Our PartnersCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinVenture Capital corporations and blockchain funds are pouring money into Web3 gaming. And there's one littl...Crypto 101 Media | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollo Endosurgery, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollo Endosurgery With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.